Virpax Pharmaceuticals Statistics
Share Statistics
Virpax Pharmaceuticals has 1.24M
shares outstanding. The number of shares has increased by 21.05%
in one year.
| Shares Outstanding | 1.24M |
| Shares Change (YoY) | 21.05% |
| Shares Change (QoQ) | 17.1% |
| Owned by Institutions (%) | 0% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 14.68K, so 1.18% of the outstanding
shares have been sold short.
| Short Interest | 14.68K |
| Short % of Shares Out | 1.18% |
| Short % of Float | 1.18% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
| PE Ratio | 0 |
| Forward PE | -0.02 |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | -0.04 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Virpax Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.63,
with a Debt / Equity ratio of 0.
| Current Ratio | 0.63 |
| Quick Ratio | 0.63 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 116.43 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-6,033,612,500 |
| Employee Count | 2 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the
last 52 weeks. The beta is 1.53, so Virpax Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 1.53 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 1.73 |
| 200-Day Moving Average | 11.65 |
| Relative Strength Index (RSI) | 19.8 |
| Average Volume (20 Days) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -12.08B |
| Net Income | -12.07B |
| EBITDA | -12.08B |
| EBIT | -12.17B |
| Earnings Per Share (EPS) | -2836.41 |
Full Income StatementBalance Sheet
The company has 1.51M in cash and 0 in
debt, giving a net cash position of 1.51M.
| Cash & Cash Equivalents | 1.51M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -71.61B |
| Total Assets | 1.56M |
| Working Capital | -913.76K |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -16.71B
and capital expenditures 0, giving a free cash flow of -16.71B.
| Operating Cash Flow | -16.71B |
| Capital Expenditures | n/a |
| Free Cash Flow | -16.71B |
| FCF Per Share | -3928.38 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
